Novel Lansoprazole-loaded Nanoparticles for the Treatment of Gastric Acid Secretion-related Ulcers: in Vitro and in Vivo Pharmacokinetic Pharmacodynamic Evaluation

Overview

Journal AAPS J

Specialty Pharmacology

Date 2014 Feb 13

PMID 24519468

Citations 4

Authors

Milind Alai

Wen Jen Lin

Affiliations

Soon will be listed here.

Abstract

The objective of this study is to combine nanoparticle design and enteric coating technique to sustain the delivery of an acid-labile drug, lansoprazole (LPZ), in the treatment of acid reflux disorders. Lansoprazole-loaded Eudragit® RS100 nanoparticles (ERSNP-LPZ) as well as poly(lactic-co-glycolic acid) (PLGA) nanoparticles (PLGANP-LPZ) were prepared using a solvent evaporation/extraction method. The effects of nanoparticle charge and permeation enhancers on lansoprazole uptake was assessed in Caco-2 cells. The confocal microscopic images revealed the successful localization of nanoparticles in the cytoplasm of Caco-2 cells. The cellular uptake of positively charged Eudragit nanoparticles was significantly higher than that of negatively charged PLGA nanoparticles, which were enhanced by sodium caprate via the transcellular pathway. Both types of nanoparticles exhibited sustained drug release behavior in vitro. The oral administration of enteric-coated capsules filled with nanoparticles sustained and prolonged the LPZ concentration up to 24 h in ulcer-induced Wistar rats, and 92.4% and 89.2% of gastric ulcers healed after a 7-day treatment with either EC-ERSNP1010-Na caprate or EC-PLGANP1005-Na caprate, respectively.

Citing Articles

Reprogramming the melanoma and immunosuppressive myeloid cells with esomeprazole-loaded PLGA nanoparticles.

Cerioli N, Bououdina W, Mereu A, Natsaridis E, Salsetta J, Cova A iScience. 2025; 28(1):111559.

PMID: 39839438 PMC: 11750290. DOI: 10.1016/j.isci.2024.111559.

Clinical Implications of Proton Pump Inhibitors and Vonoprazan Micro/Nano Drug Delivery Systems for Gastric Acid-Related Disorders and Imaging.

Setia A, Challa R, Vallamkonda B, Vaishali , Viswanadh M, Muthu M Nanotheranostics. 2024; 8(4):535-560.

PMID: 39507107 PMC: 11539181. DOI: 10.7150/ntno.100727.

The reversed intra- and extracellular pH in tumors as a unified strategy to chemotherapeutic delivery using targeted nanocarriers.

Perez-Herrero E, Fernandez-Medarde A Acta Pharm Sin B. 2021; 11(8):2243-2264.

PMID: 34522586 PMC: 8424227. DOI: 10.1016/j.apsb.2021.01.012.

Enteric-Coated Strategies in Colorectal Cancer Nanoparticle Drug Delivery System.

Wathoni N, Nguyen A, Rusdin A, Umar A, Mohammed A, Motoyama K Drug Des Devel Ther. 2020; 14:4387-4405.

PMID: 33116423 PMC: 7585804. DOI: 10.2147/DDDT.S273612.

Application of nanoparticles for oral delivery of acid-labile lansoprazole in the treatment of gastric ulcer: in vitro and in vivo evaluations.

Alai M, Lin W Int J Nanomedicine. 2015; 10:4029-41.

PMID: 26124659 PMC: 4476456. DOI: 10.2147/IJN.S82366.

References

He C, Hu Y, Yin L, Tang C, Yin C . Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials. 2010; 31(13):3657-66. DOI: 10.1016/j.biomaterials.2010.01.065. View

Dillen K, Vandervoort J, Van den Mooter G, Ludwig A . Evaluation of ciprofloxacin-loaded Eudragit RS100 or RL100/PLGA nanoparticles. Int J Pharm. 2006; 314(1):72-82. DOI: 10.1016/j.ijpharm.2006.01.041. View

Katz P, Koch F, Ballard E, Bagin R, Gautille T, Checani G . Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms. Aliment Pharmacol Ther. 2007; 25(2):197-205. DOI: 10.1111/j.1365-2036.2006.03191.x. View

Costa P, Sousa Lobo J . Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001; 13(2):123-33. DOI: 10.1016/s0928-0987(01)00095-1. View

Yadav K, Sawant K . Formulation optimization of etoposide loaded PLGA nanoparticles by double factorial design and their evaluation. Curr Drug Deliv. 2010; 7(1):51-64. DOI: 10.2174/156720110790396517. View

Cartiera M, Johnson K, Rajendran V, Caplan M, Saltzman W . The uptake and intracellular fate of PLGA nanoparticles in epithelial cells. Biomaterials. 2009; 30(14):2790-8. PMC: 3195413. DOI: 10.1016/j.biomaterials.2009.01.057. View

Cetin M, Atila A, Sahin S, Vural I . Preparation and characterization of metformin hydrochloride loaded-Eudragit®RSPO and Eudragit®RSPO/PLGA nanoparticles. Pharm Dev Technol. 2011; 18(3):570-6. DOI: 10.3109/10837450.2011.604783. View

Horn J, Howden C . Review article: similarities and differences among delayed-release proton-pump inhibitor formulations. Aliment Pharmacol Ther. 2005; 22 Suppl 3:20-4. DOI: 10.1111/j.1365-2036.2005.02714.x. View

Alai M, Lin W . A novel nanoparticulate system for sustained delivery of acid-labile lansoprazole. Colloids Surf B Biointerfaces. 2013; 111:453-9. DOI: 10.1016/j.colsurfb.2013.06.035. View

10.

Panyam J, Sahoo S, Prabha S, Bargar T, Labhasetwar V . Fluorescence and electron microscopy probes for cellular and tissue uptake of poly(D,L-lactide-co-glycolide) nanoparticles. Int J Pharm. 2003; 262(1-2):1-11. DOI: 10.1016/s0378-5173(03)00295-3. View

11.

Wang H, Jia Y, Hu W, Jiang H, Zhang J, Zhang L . Effect of preparation conditions on the size and encapsulation properties of mPEG-PLGA nanoparticles simultaneously loaded with vincristine sulfate and curcumin. Pharm Dev Technol. 2012; 18(3):694-700. DOI: 10.3109/10837450.2012.696267. View

12.

Laroui H, Wilson D, Dalmasso G, Salaita K, Murthy N, Sitaraman S . Nanomedicine in GI. Am J Physiol Gastrointest Liver Physiol. 2010; 300(3):G371-83. PMC: 3064120. DOI: 10.1152/ajpgi.00466.2010. View

13.

Adibkia K, Javadzadeh Y, Dastmalchi S, Mohammadi G, Niri F, Alaei-Beirami M . Naproxen-eudragit RS100 nanoparticles: preparation and physicochemical characterization. Colloids Surf B Biointerfaces. 2010; 83(1):155-9. DOI: 10.1016/j.colsurfb.2010.11.014. View

14.

Dong Y, Feng S . Poly(d,l-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs. Biomaterials. 2005; 26(30):6068-76. DOI: 10.1016/j.biomaterials.2005.03.021. View

15.

Devarajan P, Sonavane G . Preparation and in vitro/in vivo evaluation of gliclazide loaded Eudragit nanoparticles as a sustained release carriers. Drug Dev Ind Pharm. 2007; 33(2):101-11. DOI: 10.1080/03639040601096695. View

16.

Song X, Zhao Y, Wu W, Bi Y, Cai Z, Chen Q . PLGA nanoparticles simultaneously loaded with vincristine sulfate and verapamil hydrochloride: systematic study of particle size and drug entrapment efficiency. Int J Pharm. 2007; 350(1-2):320-9. DOI: 10.1016/j.ijpharm.2007.08.034. View

17.

Altan E, Blondeau K, Pauwels A, Farre R, Tack J . Evolving pharmacological approaches in gastroesophageal reflux disease. Expert Opin Emerg Drugs. 2012; 17(3):347-59. DOI: 10.1517/14728214.2012.702753. View

18.

Tarnawski A . Cellular and molecular mechanisms of gastrointestinal ulcer healing. Dig Dis Sci. 2005; 50 Suppl 1:S24-33. DOI: 10.1007/s10620-005-2803-6. View

19.

Hassani S, Hasani S, Pellequer Y, Lamprecht A . Selective adhesion of nanoparticles to inflamed tissue in gastric ulcers. Pharm Res. 2009; 26(5):1149-54. DOI: 10.1007/s11095-009-9834-1. View

20.

Adibkia K, Siahi Shadbad M, Nokhodchi A, Javadzedeh A, Barzegar-Jalali M, Barar J . Piroxicam nanoparticles for ocular delivery: physicochemical characterization and implementation in endotoxin-induced uveitis. J Drug Target. 2007; 15(6):407-16. DOI: 10.1080/10611860701453125. View